Korro Bio, Inc. (KRRO) stock
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.71−0.90 (-6.61%)
Close on Nov 16, 2026Market cap $187.16MP/E –Yield –
Korro Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Korro Bio's profit margin for the twelve months ending Jun 30, 2026 was -4477.1%. For fiscal 2025 it was -1834.5%, against -3680.4% the year before. The highest annual figure on record is -64.8% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1834.5% | +1845.9 |
| FY2024 | Dec 31, 2024 | -3680.4% | −3078.4 |
| FY2021 | Dec 31, 2021 | -602.0% | −530.3 |
| FY2020 | Dec 31, 2020 | -71.7% | −6.9 |
| FY2019 | Dec 31, 2019 | -64.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -3873.2% | −2939.8 |
| Q3 FY2025 | Sep 30, 2025 | -1657.0% | −1469.5 |
| Q2 FY2025 | Jun 30, 2025 | -1765.1% | −1327.0 |
| Q1 FY2025 | Mar 31, 2025 | -917.1% | −814.3 |
| Q4 FY2024 | Dec 31, 2024 | -933.5% | −886.0 |
| Q2 FY2021 | Jun 30, 2021 | -187.5% | −116.8 |
| Q1 FY2021 | Mar 31, 2021 | -438.1% | −370.4 |
| Q4 FY2020 | Dec 31, 2020 | -102.8% | +13.8 |
| Q3 FY2020 | Sep 30, 2020 | -47.5% | −45.1 |
| Q2 FY2020 | Jun 30, 2020 | -70.7% | – |
| Q1 FY2020 | Mar 31, 2020 | -67.6% | – |
| Q4 FY2019 | Dec 31, 2019 | -116.6% | – |
| Q3 FY2019 | Sep 30, 2019 | -2.4% | – |
See a number that looks wrong?